STipe Therapeutics appoints Dr Richard Sainson as Chief Scientific Officer to Lead Research and Discovery
AARHUS, Denmark, May 31, 2022 (GLOBE NEWSWIRE) -- STipe Therapeutics (STipe), a company with a novel approach to leverage the STimulator of INterferon Genes (STING) Pathway, a major driver of the innate immune response, by a unique sensitization mechanism, today announced the strengthening of its leadership team with the appointment of Dr Richard Sainson as Chief Scientific Officer (CSO), effective June 6, 2022. He will be based in Aarhus, Denmark and report to Dr Claus Olesen, STipe’s Chief Executive Officer (CEO). As CSO, Dr Sainson will lead the research and advancement of the Company’s innovative science and platform technology.
AARHUS, Denmark, May 31, 2022 (GLOBE NEWSWIRE) -- STipe Therapeutics (STipe), a company with a novel approach to leverage the STimulator of INterferon Genes (STING) Pathway, a major driver of the innate immune response, by a unique sensitization mechanism, today announced the strengthening of its leadership team with the appointment of Dr Richard Sainson as Chief Scientific Officer (CSO), effective June 6, 2022. He will be based in Aarhus, Denmark and report to Dr Claus Olesen, STipe’s Chief Executive Officer (CEO). As CSO, Dr Sainson will lead the research and advancement of the Company’s innovative science and platform technology.
Sangri Today
Sangri Today is a Weekly Bilingual Newspaper and website of news and current affairs that publishes news reports from various places, from general reports.
